JENTADUETO Drug Patent Profile

When do Jentadueto patents expire, and what generic alternatives are available?

Jentadueto is a drug marketed by Boehringer Ingelheim and is included in two NDAs. There are eleven patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and ninety-one patent family members in forty countries.

The generic ingredient in JENTADUETO is linagliptin; metformin hydrochloride. There are nineteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the linagliptin; metformin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Jentadueto

A generic version of JENTADUETO was approved as linagliptin; metformin hydrochloride by SUNSHINE on August 30^th, 2021.

Summary for JENTADUETO

International Patents:	291
US Patents:	9
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	7
Clinical Trials:	1
Patent Applications:	122
Drug Prices:	Drug price information for JENTADUETO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JENTADUETO
What excipients (inactive ingredients) are in JENTADUETO?	JENTADUETO excipients list
DailyMed Link:	JENTADUETO at DailyMed

See drug prices for JENTADUETO

Recent Clinical Trials for JENTADUETO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Boehringer Ingelheim	Phase 1

See all JENTADUETO clinical trials

Pharmacology for JENTADUETO

Drug Class	Biguanide Dipeptidyl Peptidase 4 Inhibitor
Mechanism of Action	Dipeptidyl Peptidase 4 Inhibitors

Paragraph IV (Patent) Challenges for JENTADUETO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JENTADUETO	Tablets	linagliptin; metformin hydrochloride	2.5 mg/500 mg 2.5 mg/850 mg 2.5 mg/1000 mg	201281	8	2015-05-04

US Patents and Regulatory Information for JENTADUETO

JENTADUETO is protected by nine US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016		RX	Yes	No	8,883,805*PED				Y
Boehringer Ingelheim	JENTADUETO	linagliptin; metformin hydrochloride	TABLET;ORAL	201281-002	Jan 30, 2012	AB	RX	Yes	No
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-002	May 27, 2016		RX	Yes	Yes	9,173,859*PED				Y

Expired US Patents for JENTADUETO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	JENTADUETO	linagliptin; metformin hydrochloride	TABLET;ORAL	201281-002	Jan 30, 2012	7,078,381
Boehringer Ingelheim	JENTADUETO	linagliptin; metformin hydrochloride	TABLET;ORAL	201281-003	Jan 30, 2012	7,459,428
Boehringer Ingelheim	JENTADUETO	linagliptin; metformin hydrochloride	TABLET;ORAL	201281-001	Jan 30, 2012	8,119,648

EU/EMA Drug Approvals for JENTADUETO

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Boehringer Ingelheim International GmbH	Jentadueto	linagliptin, metformin hydrochloride	EMEA/H/C/002279Treatment of adult patients with type-2 diabetes mellitus:Jentadueto is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of linagliptin and metformin.Jentadueto is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.	Authorised	no	no	no	2012-07-19

International Patents for JENTADUETO

When does loss-of-exclusivity occur for JENTADUETO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Japan

Mexico

Morocco

New Zealand

Peru

Poland

South Africa

South Korea

Spain

Taiwan

Tunisia

Turkey

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering JENTADUETO around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	071175
Australia	2009232043
Brazil	PI0911273

Supplementary Protection Certificates for JENTADUETO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1532149	C300504	Netherlands		PRODUCT NAME: LINAGLIPTINE, DESGEWENST IN DE VORM VAN ZOUT; REGISTRATION NO/DATE: EU/1/11/707/001-011 20110824
1532149	1190035-4	Sweden		PERIOD OF VALIDITY (FROM - UNTIL): 20230819 - 20260829
1532149	PA2011013	Lithuania		PRODUCT NAME: LINAGLIPTINUM; REGISTRATION NO/DATE: EU/1/11/707/001, 2011 08 24 EU/1/11/707/002, 2011 08 24 EU/1/11/707/003, 2011 08 24 EU/1/11/707/004, 2011 08 24 EU/1/11/707/005, 2011 08 24 EU/1/11/707/006, 2011 08 24 EU/1/11/707/007, 2011 08 24 EU/1/11/707/008, 2011 08 24 EU/1/11/707/00 2011082

Last updated: June 24, 2026

JENTADUETO market dynamics and financial trajectory (Boehringer Ingelheim/Lilly metformin + linagliptin)

JENTADUETO (metformin hydrochloride + linagliptin) is a fixed-dose combination for type 2 diabetes that has faced sustained competitive pressure from GLP-1 receptor agonists, SGLT2 inhibitors, and incretin-based combinations. Financial trajectory is best characterized as “mature product, margin and volume pressured by class shifts,” with most value tied to long-lived generic entry dynamics around metformin and to the persistence of linagliptin brand differentiation. The sales base has also been influenced by payer formulary management, step-therapy adoption, and volume migration within DPP-4 inhibitor portfolios.

Below is the market landscape, exclusivity and competitive risks, and the financial drivers that determine near- to mid-term revenue outcomes for JENTADUETO.

---

How is JENTADUETO performing commercially and what revenue drivers matter most?

JENTADUETO’s revenue is determined by three linked variables: (1) unit demand for DPP-4 inhibitor therapy within the broader type 2 diabetes market, (2) share capture inside payer tiers versus competing oral combination regimens, and (3) net price realization after rebates, discounts, and contract-specific offsets.

Key commercial drivers

• Formulary placement and utilization management: DPP-4 inhibitor combinations are increasingly positioned as later-line or “alternative” therapy under many payer policies, particularly after broad uptake of GLP-1 RAs and SGLT2 inhibitors.
• Combination convenience versus therapeutic shift: Fixed-dose combination improves adherence relative to separate pills, but does not protect against switching when guideline and payer incentives favor injectable or cardiorenal outcome–linked agents.
• Net pricing versus list price: In mature diabetes markets, list price often understates realized revenue. Contracted price and rebate structure can dominate year-to-year trajectory.
• Competition from other oral DPP-4 regimens: Even if GLP-1/SGLT2 are dominant, DPP-4 combinations remain in formularies where cost sensitivity is high.

What typically changes year to year

For a product like JENTADUETO, the biggest annual deltas usually come from:

• payer tightening (coverage criteria, step edits),
• migration to other incretin combinations,
• loss or maintenance of share within specific covered segments (for example, metformin-tolerant patients already on metformin, or those seeking dual oral therapy),
• generic metformin utilization patterns.

---

What market dynamics are pressuring DPP-4 fixed-dose combinations like JENTADUETO?

The diabetes market has shifted toward agents with stronger clinical and payer value narratives, especially GLP-1 RAs and SGLT2 inhibitors. DPP-4 inhibitors have retained a role, but their growth ceiling has tightened.

Demand shift by prescriber and payer behavior

• Clinical practice patterns: Newer agents often displace DPP-4 options, particularly when cardiovascular or renal comorbidity is present.
• Payer incentives: Many formularies favor preferencing strategies that rank GLP-1 RAs and SGLT2 inhibitors above DPP-4 inhibitors when budget permits.
• Switching dynamics: Patients already stabilized on DPP-4 therapy can persist, but switch rates rise as alternative combinations offer better tolerability, weight benefit, or outcomes-linked labeling.

Competitive mechanics versus brand DPP-4

• Oral class competition: Within oral therapy, DPP-4 combinations compete on incremental efficacy, tolerability, and dosing simplicity.
• Price pressure: Even where DPP-4 agents remain covered, competitive rebating can compress net unit revenue.
• Therapy sequencing: Many plans structure coverage so that DPP-4 combination lines follow failure or intolerance of preferred classes.

---

Which products most directly compete with JENTADUETO in the type 2 diabetes fixed-dose oral segment?

JENTADUETO competes as a metformin plus DPP-4 inhibitor fixed-dose product, most notably in therapeutic adjacency with other DPP-4 fixed-dose combinations and, indirectly, with GLP-1 and SGLT2 combination strategies that may be favored by payers.

Direct oral comparator set (fixed-dose / DPP-4 adjacency)

• Metformin + other DPP-4 inhibitors in fixed-dose form (class analogs).
• Standalone metformin regimens plus add-on DPP-4 therapy (separate pills as a convenience substitute).

Indirect but high-impact competitors

• GLP-1 receptor agonists (including once-weekly agents and oral GLP-1 formulations where covered).
• SGLT2 inhibitors and fixed-dose oral combinations that displace oral dual therapy choices.

---

How does JENTADUETO compare with alternative metformin-based combinations on payer access and patient selection?

Payer access tends to favor either:

1. low-cost oral dual therapy options where outcomes narratives are not a payer requirement, or
2. preferenced outcomes-driven therapies when the plan’s contracts support them.

Practical placement patterns

• Cost-sensitive plans: More likely to maintain DPP-4 regimens but push utilization through step edits and prior authorization.
• Outcome-focused plans: More likely to steer patients away from DPP-4 toward GLP-1 or SGLT2, especially in patients with ASCVD, CKD, or heart failure.

---

What is the patent and exclusivity backdrop that influences JENTADUETO’s financial trajectory?

JENTADUETO contains metformin (widely generic) and linagliptin (brand-originated). Financial outcomes are therefore shaped less by metformin and more by linagliptin’s patent landscape, plus formulation and method-of-use protections for the fixed-dose combination.

Core exclusivity logic for a fixed-dose combo

• Metformin: generic availability caps the value of the metformin component on its own.
• Linagliptin component: brand value persists until linagliptin-related patents and regulatory exclusivities run, and until combination-specific barriers are cleared for generic fixed-dose products.

What to expect once barriers clear

• Price compression accelerates as fixed-dose combination generics launch.
• Patient adherence can keep utilization stable initially, but net revenue falls with lower-priced entrants.
• Brand often responds via contracting, co-pay support (where allowed), or targeted retention segments.

---

When does JENTADUETO lose exclusivity and what generic entry risks exist?

The financial trajectory hinges on timing of combination-level generic clearance, not just active-ingredient clearance. For JENTADUETO, generic entry risk typically emerges in phases:

1. generic linagliptin availability,
2. combination fixed-dose product approvals, and
3. potential label carve-outs or formulation-specific launch timing.

Paragraph IV and settlement dynamics

For combination products, Paragraph IV litigation typically aims to delay FDA approval and launch of ANDA generics. The market impact is often non-linear: settlements can delay launches and preserve price, but once resolutions expire, multiple entrants can hit quickly.

---

What is the Orange Book status of JENTADUETO and how does it map to launch timing?

Orange Book listing determines what patents are asserted for FDA approval timing for generic challengers. For JENTADUETO, the relevant patent set is normally a mix of:

• drug substance or drug product patents tied to linagliptin,
• combination/product patents specific to metformin/linagliptin fixed-dose tablets,
• manufacturing and formulation patents that can slow or block specific generic designs.

How Orange Book listings affect financial outcomes

• More listed patents extending different claim scopes increase blocking power.
• Fewer but strong composition claims still matter if they are difficult to design around.
• Expiration distribution determines whether brand faces a single “cliff” or multiple launch waves.

---

What formulations of JENTADUETO are protected and what dosage strengths matter for competition?

Fixed-dose combinations typically have multiple strengths (for example, metformin dose variants paired with linagliptin dose). Patent protection can be strength-specific if formulation or composition claims depend on excipients or manufacturing processes, or if product patents are drafted around specific strengths.

Competitive relevance

• If generic applicants are cleared for only some strengths initially, revenue can remain partially protected while remaining strengths face delay.
• If generic is cleared broadly across strengths, revenue compression is more immediate.

---

What patent litigation affects JENTADUETO and how do settlements usually change the revenue curve?

Patent litigation is a principal determinant of whether a brand experiences:

• delayed generic launch (flatter revenue decline), or
• earlier generic launch (steeper revenue decline).

Typical settlement impacts on market dynamics

• “First-filer” settlements: can cap the number of approved generics and delay first-wave entry.
• Design-around opportunities: can enable later entrants to launch at different times even if one challenger settles.

---

How does FDA regulatory status influence JENTADUETO’s competitive and financial timeline?

FDA status affects only the timing of approval and labeling transitions, but it strongly influences launch sequencing and payer adoption.

Regulatory mechanisms that matter

• ANDAs for fixed-dose generics: require bioequivalence and compliance with patent carve-outs or expirations depending on Orange Book certifications.
• Switching and formulary update cycles: even after FDA approval, payers may delay adoption due to pharmacy policy and contracting cycles.

---

What is the biosimilar risk for JENTADUETO?

JENTADUETO is a small-molecule combination product, so biosimilar risk does not apply. Competitive pressure instead comes from small-molecule generics and authorized generics.

---

What generic entry scenarios are most likely for JENTADUETO and what revenue impact do they drive?

Three scenarios generally define revenue impact for fixed-dose oral diabetes combinations:

Scenario A: Broad fixed-dose generic entry across strengths

• fastest price compression,
• strongest volume shift to generics,
• steep revenue decline after launch.

Scenario B: Partial strength entry first

• moderated revenue decline,
• slower payer substitution,
• brand retains share in non-entered strengths.

Scenario C: Delayed or limited entry due to patent barriers or regulatory standoffs

• delayed price compression,
• more time for payer contracting around brand value,
• higher odds of maintaining net revenue into the next contracting cycle.

---

Which company(s) historically capture share gains in metformin + DPP-4 fixed-dose products after launch?

Post-exclusivity performance is driven by:

• number of ANDA filers,
• manufacturing capacity,
• ability to secure pharmacy distribution and favorable contracts.

In oral solid dose markets, revenue capture often concentrates among large generic manufacturers with ready-to-launch capabilities.

---

What are the key financial implications for investors and licensing partners assessing JENTADUETO?

For licensing and investment decisions, the crucial questions are:

• How much of JENTADUETO revenue is protected from near-term fixed-dose generic displacement?
• Is demand being structurally reduced by class migration to GLP-1/SGLT2, or stabilized by durable DPP-4 segments?
• Will remaining patent barriers delay generics enough to preserve contract pricing?

Business-risk profile

• Downside drivers: faster-than-expected payer shift to preferred classes, earlier-than-modeled generic launch, and aggressive rebate erosion.
• Upside drivers: delayed fixed-dose generic entry, stronger-than-expected retention in specific patient segments, and favorable payer contracting.

---

Key Takeaways

• JENTADUETO operates in a mature, increasingly pressured diabetes segment as payers and clinicians migrate toward GLP-1 RAs and SGLT2 inhibitors.
• Revenue trajectory is determined more by net pricing and formulary positioning than by metformin exposure, because metformin is largely generic.
• Financial risk is concentrated in the timing and scope of fixed-dose generic entry for metformin/linagliptin, which is shaped by Orange Book-listed patents, litigation, and settlement outcomes.
• Competitive outcomes depend on whether generic entrants launch broadly across strengths or initially only cover part of the portfolio, which changes the steepness of revenue decline.

---

FAQs

1) What net price pressure typically drives the fastest revenue decline for mature DPP-4 fixed-dose brands?
Rebate and contracting erosion tied to generic threats and formulary re-tiering.

2) Does generic metformin availability alone eliminate JENTADUETO brand value?
No. Brand value persists due to linagliptin component differentiation and fixed-dose combination protections.

3) How do payer step edits affect JENTADUETO persistence after new GLP-1/SGLT2 launches?
They can restrict initiation and new starts, reducing future demand even when stable patients continue therapy.

4) What launch pattern is more damaging to brand revenue: first strength or full-strength fixed-dose coverage?
Full-strength coverage is more damaging because it enables broader formulary substitution.

5) What is the principal competitive threat category for JENTADUETO besides small-molecule generics?
Class-level substitution toward GLP-1 receptor agonists and SGLT2 inhibitors.

---

References (APA)

No sources were provided in the prompt, and no citations are included.

DrugChatter Q&A for JENTADUETO

Jentadueto 2 5 1000 mg price?
Jentadueto 2.5/500 mg price?